{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:58:31Z","timestamp":1778047111933,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Orthopaedics and Traumatology Research Foundation","award":["557"],"award-info":[{"award-number":["557"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-025-01645-x","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:17:07Z","timestamp":1765279027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Renal function predicts 12-month response to romosozumab readministration after denosumab in women with osteoporosis"],"prefix":"10.1007","volume":"21","author":[{"given":"Takaomi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"5","key":"1645_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","volume":"42","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Hara M, Shimanoe C, Morimoto T, Masaaki M, Ito K et al (2024) Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Miner Metab 42(5):492\u2013502. https:\/\/doi.org\/10.1007\/s00774-024-01531-5","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1645_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00774-025-01590-2","volume":"43","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T (2025) Sequential and combination therapy with romosozumab. J Bone Miner Metab 43(1):10\u201317. https:\/\/doi.org\/10.1007\/s00774-025-01590-2","journal-title":"J Bone Miner Metab"},{"key":"1645_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study. Bone 162:116480. https:\/\/doi.org\/10.1016\/j.bone.2022.116480","journal-title":"Bone"},{"issue":"2","key":"1645_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/jbmr\/zjae196","volume":"2","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T, Nakamura Y (2025) Verifying the effectiveness of romosozumab re-administration on bone mineral density. J Bone Miner Res 2(2):201\u2013210. https:\/\/doi.org\/10.1093\/jbmr\/zjae196","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1645_CR5","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30(12):2437\u20132448. https:\/\/doi.org\/10.1007\/s00198-019-05146-9","journal-title":"Osteoporos Int"},{"issue":"10","key":"1645_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39(10):1393\u2013405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1645_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00774-024-01570-y","volume":"43","author":"A Tominaga","year":"2025","unstructured":"Tominaga A, Wada K, Kato Y, Okazaki K (2025) Responders and non-responders to romosozumab treatment. J Bone Miner Metab 43(1):18\u201321. https:\/\/doi.org\/10.1007\/s00774-024-01570-y","journal-title":"J Bone Miner Metab"},{"key":"1645_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117708","author":"T Kobayashi","year":"2025","unstructured":"Kobayashi T, Kobayakawa T, Nakamura Y (2025) Age-related response to 12-month romosozumab in treatment-na\u00efve Japanese women aged 55\u2013100 years with primary osteoporosis. Bone. https:\/\/doi.org\/10.1016\/j.bone.2025.117708","journal-title":"Bone"},{"issue":"3","key":"1645_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","volume":"34","author":"M Kashii","year":"2023","unstructured":"Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34(3):563\u2013572. https:\/\/doi.org\/10.1007\/s00198-022-06642-1","journal-title":"Osteoporos Int"},{"issue":"5","key":"1645_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/mr\/roae008","volume":"34","author":"K Hattori","year":"2024","unstructured":"Hattori K, Kanayama Y (2024) Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab. Mod Rheumatol 34(5):1047\u20131055. https:\/\/doi.org\/10.1093\/mr\/roae008","journal-title":"Mod Rheumatol"},{"key":"1645_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117164","volume":"186","author":"K Mineta","year":"2024","unstructured":"Mineta K, Nishisho T, Okada M, Kamada M, Sairyo K (2024) Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: an observational study. Bone 186:117164. https:\/\/doi.org\/10.1016\/j.bone.2024.117164","journal-title":"Bone"},{"key":"1645_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S et al (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"issue":"9","key":"1645_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S, Studer U, Steiner C, Ziswiler HR et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613. https:\/\/doi.org\/10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"issue":"4","key":"1645_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3349\/ymj.2023.0535","volume":"66","author":"A Kuwabara","year":"2025","unstructured":"Kuwabara A, Inage K, Yamashita M, Orita S, Eguchi Y, Shiga Y et al (2025) Predictive factors for increased bone density following romosozumab administration based on pre-administration blood test results. Yonsei Med J 66(4):226\u2013232. https:\/\/doi.org\/10.3349\/ymj.2023.0535","journal-title":"Yonsei Med J"},{"key":"1645_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1523-1755.2005.09500.x","volume":"95","author":"EA Friedman","year":"2005","unstructured":"Friedman EA (2005) Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl 95:S1-7. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09500.x","journal-title":"Kidney Int Suppl"},{"key":"1645_CR16","doi-asserted-by":"publisher","unstructured":"Waitupu A, Pratiwi L, Sutanto H, Santoso D, Hertanto DM (2025) Molecular pathophysiology of chronic kidney disease-mineral and bone disorder: Focus on the fibroblast growth factor 23-Klotho axis and bone turnover dynamics. Exp Physiol. In Press. https:\/\/doi.org\/10.1113\/EP092401.","DOI":"10.1113\/EP092401"},{"key":"1645_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-016-0024-4","volume":"2","author":"Y Asamiya","year":"2016","unstructured":"Asamiya Y, Tsuchiya K, Nitta K (2016) Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder. Ren Replace Ther 2:8. https:\/\/doi.org\/10.1186\/s41100-016-0024-4","journal-title":"Ren Replace Ther"},{"key":"1645_CR18","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group https:\/\/iris.who.int\/handle\/10665\/39142. Accessed 7 Sept 2025"},{"issue":"1","key":"1645_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18(1):18\u201323. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.18","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1645_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00774-010-0188-x","volume":"29","author":"M Shiraki","year":"2011","unstructured":"Shiraki M, Kuroda T, Miyakawa N, Fujinawa N, Tanzawa K, Ishizuka A et al (2011) Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). J Bone Miner Metab 29(1):37\u201343. https:\/\/doi.org\/10.1007\/s00774-010-0188-x","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"1645_CR21","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90(3):1583\u20131587. https:\/\/doi.org\/10.1210\/jc.2004-0826","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1645_CR22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1645_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10546","volume":"5","author":"F Cosman","year":"2021","unstructured":"Cosman F, Libanati C, Deignan C, Yu Z, Wang Z, Ferrari S et al (2021) Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals. JBMR Plus 5(11):e10546. https:\/\/doi.org\/10.1002\/jbm4.10546","journal-title":"JBMR Plus"},{"issue":"8","key":"1645_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8(8):672\u201382. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1645_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00774-020-01147-5","volume":"39","author":"A Miyauchi","year":"2021","unstructured":"Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C et al (2021) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab 39(2):278\u2013288. https:\/\/doi.org\/10.1007\/s00774-020-01147-5","journal-title":"J Bone Miner Metab"},{"key":"1645_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117627","volume":"201","author":"Y Etani","year":"2025","unstructured":"Etani Y, Noguchi T, Yukishima T, Kobayakawa T, Kashii M, Okamura G et al (2025) Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-na\u00efve primary osteoporosis: a retrospective cohort study. Bone 201:117627. https:\/\/doi.org\/10.1016\/j.bone.2025.117627","journal-title":"Bone"},{"key":"1645_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep 14:101068. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"issue":"3","key":"1645_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31(3):247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"1645_CR29","first-page":"357","volume":"70","author":"Y Hidaka","year":"2013","unstructured":"Hidaka Y (2013) Basic performance and reference range of Elecsys total P1NP. Jpn J Med Pharm Sci 70(2):357\u201365","journal-title":"Jpn J Med Pharm Sci"},{"key":"1645_CR30","unstructured":"Japanese Committee for Clinical Laboratory Standards (JCCLS). Common reference intervals for major clinical laboratory tests in Japan. https:\/\/www.jccls.org\/wp-content\/uploads\/2020\/11\/public_20190222.pdf. Accessed 18 Oct 2025."},{"key":"1645_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-015-0077-3","volume":"15","author":"Y Nakamura","year":"2015","unstructured":"Nakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Uchiyama S, Taguchi A et al (2015) Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord 15:81. https:\/\/doi.org\/10.1186\/s12902-015-0077-3","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"1645_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jos.2022.03.011","volume":"28","author":"T Kobayashi","year":"2023","unstructured":"Kobayashi T, Morimoto T, Ono R, Otani K, Mawatari M (2023) Is grip strength useful in screening to predict the severity of locomotive syndrome? J Orthop Sci 28(4):880\u2013885. https:\/\/doi.org\/10.1016\/j.jos.2022.03.011","journal-title":"J Orthop Sci"},{"issue":"1","key":"1645_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12874-024-02198-2","volume":"24","author":"M Hassanzad","year":"2024","unstructured":"Hassanzad M, Hajian-Tilaki K (2024) Methods of determining optimal cut-point of diagnostic biomarkers with application of clinical data in ROC analysis: an update review. BMC Med Res Methodol 24(1):84. https:\/\/doi.org\/10.1186\/s12874-024-02198-2","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"1645_CR34","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1210\/jc.2017-02669","volume":"103","author":"DW Dempster","year":"2018","unstructured":"Dempster DW, Brown JP, Fahrleitner-Pammer A, Kendler D, Rizzo S, Valter I et al (2018) Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 103(7):2498\u2013509. https:\/\/doi.org\/10.1210\/jc.2017-02669","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1645_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jbm4.10117","volume":"2","author":"MJ Damasiewicz","year":"2018","unstructured":"Damasiewicz MJ, Nickolas TL (2018) Rethinking bone disease in kidney disease. JBMR Plus 2(6):309\u2013322. https:\/\/doi.org\/10.1002\/jbm4.10117","journal-title":"JBMR Plus"},{"issue":"8","key":"1645_CR36","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u201345. https:\/\/doi.org\/10.1002\/jbmr.4563","journal-title":"J Bone Miner Res"},{"key":"1645_CR37","unstructured":"U.S. Food & Drug Administration. Prolia (denosumab): Drug safety communication \u2013 FDA adds boxed warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/prolia-denosumab-drug-safety-communication-fda-adds-boxed-warning-increased-risk-severe-hypocalcemia. Accessed\u00a07 Sept 2025"},{"issue":"10","key":"1645_CR38","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1093\/ckj\/sfab016","volume":"14","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Shinkawa K, Yanagita M, Kawakami K (2021) Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data. Clin Kidney J 14(10):2197\u20132202. https:\/\/doi.org\/10.1093\/ckj\/sfab016","journal-title":"Clin Kidney J"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01645-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:02:04Z","timestamp":1765321324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01645-x","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were following the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Takaomi Kobayashi, Tomonori Kobayakawa, and Yukio Nakamura declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}